BR112012007509A2 - derivados pirazóis que modulam estearoil-coa dessaturase - Google Patents

derivados pirazóis que modulam estearoil-coa dessaturase

Info

Publication number
BR112012007509A2
BR112012007509A2 BR112012007509A BR112012007509A BR112012007509A2 BR 112012007509 A2 BR112012007509 A2 BR 112012007509A2 BR 112012007509 A BR112012007509 A BR 112012007509A BR 112012007509 A BR112012007509 A BR 112012007509A BR 112012007509 A2 BR112012007509 A2 BR 112012007509A2
Authority
BR
Brazil
Prior art keywords
modulate
pyrazole derivatives
coa desaturase
derivatives
stearoyl coa
Prior art date
Application number
BR112012007509A
Other languages
English (en)
Portuguese (pt)
Inventor
Jianmin Fu
Natalia Pokrovskaia
Natalie Dales
Qi Jia
Shaoyi Sun
Zaihui Zhang
Original Assignee
Novartis Ag
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43066810&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012007509(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Xenon Pharmaceuticals Inc filed Critical Novartis Ag
Publication of BR112012007509A2 publication Critical patent/BR112012007509A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112012007509A 2009-10-01 2010-10-01 derivados pirazóis que modulam estearoil-coa dessaturase BR112012007509A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24763409P 2009-10-01 2009-10-01
PCT/EP2010/064672 WO2011039358A1 (en) 2009-10-01 2010-10-01 Pyrazole derivatives which modulate stearoyl-coa desaturase

Publications (1)

Publication Number Publication Date
BR112012007509A2 true BR112012007509A2 (pt) 2016-11-22

Family

ID=43066810

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012007509A BR112012007509A2 (pt) 2009-10-01 2010-10-01 derivados pirazóis que modulam estearoil-coa dessaturase

Country Status (23)

Country Link
US (1) US20130011361A1 (enExample)
EP (1) EP2483264A1 (enExample)
JP (1) JP2013506638A (enExample)
KR (1) KR20120080226A (enExample)
CN (1) CN102574841A (enExample)
AU (1) AU2010302577A1 (enExample)
BR (1) BR112012007509A2 (enExample)
CA (1) CA2776294A1 (enExample)
CL (1) CL2012000797A1 (enExample)
CO (1) CO6761294A2 (enExample)
CR (1) CR20120134A (enExample)
EA (1) EA201200545A1 (enExample)
EC (1) ECSP12011837A (enExample)
IL (1) IL218294A0 (enExample)
IN (1) IN2012DN01913A (enExample)
MA (1) MA33693B1 (enExample)
MX (1) MX2012003938A (enExample)
PE (1) PE20121439A1 (enExample)
PH (1) PH12012500648A1 (enExample)
SG (1) SG178869A1 (enExample)
TN (1) TN2012000085A1 (enExample)
WO (1) WO2011039358A1 (enExample)
ZA (1) ZA201201390B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2850836A1 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
CN110099898B (zh) 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
CN110392833A (zh) 2017-01-06 2019-10-29 优曼尼蒂治疗公司 治疗神经病症的方法
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
CN112312913B (zh) 2018-03-23 2024-03-08 詹森药业有限公司 化合物和其用途
CN113906019A (zh) 2019-01-24 2022-01-07 优曼尼蒂治疗公司 化合物及其用途
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
GB202012969D0 (en) * 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058360A2 (en) 1999-03-29 2000-10-05 Uutech Limited Analogs of gastric inhibitory peptide and their use for treatment of diabetes
CZ296858B6 (cs) 1999-09-28 2006-07-12 Bayer Corporation Agonisté receptoru 3 (R3) hypofyzárního peptidu aktivujícího adenylátcyklázu (PACAP) a jejich farmaceutické pouzití
ATE475718T1 (de) 2000-02-24 2010-08-15 Xenon Pharmaceuticals Inc Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika
US7232662B2 (en) 2000-09-26 2007-06-19 Xenon Pharmaceuticals Inc. Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5
CA2580855A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP4958784B2 (ja) * 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ステアロイル−CoAデサチュラーゼ酵素によって媒介される疾患の処置のための複素環誘導体
WO2007046867A2 (en) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
RU2009109147A (ru) * 2006-08-15 2010-09-27 Новартис АГ (CH) Органические соединения
RU2009110254A (ru) * 2006-08-24 2010-09-27 Новартис АГ (CH) Производные 2-(пиразин-2-ил)тиазола и 2-(1н-пиразол-3-ил)тиразола и связанные с ним соединения в качестве ингибиторов стеароил-соа десатуразы для лечения метаболических, сердечно-сосудистых и других нарушений
EP2066664A1 (en) * 2006-09-22 2009-06-10 Novartis AG Heterocyclic organic compounds
US8068738B2 (en) * 2007-02-21 2011-11-29 Tte Technology, Inc. System and method for decoding infra-red (IR) signals
MX2010009158A (es) * 2008-02-20 2010-09-24 Novartis Ag Inhibidores heterociclicos de estearoil-coa-desaturasa.

Also Published As

Publication number Publication date
EP2483264A1 (en) 2012-08-08
EA201200545A1 (ru) 2012-12-28
TN2012000085A1 (en) 2013-09-19
JP2013506638A (ja) 2013-02-28
WO2011039358A1 (en) 2011-04-07
CN102574841A (zh) 2012-07-11
CA2776294A1 (en) 2011-04-07
KR20120080226A (ko) 2012-07-16
ZA201201390B (en) 2012-10-31
CR20120134A (es) 2012-05-17
MX2012003938A (es) 2012-08-03
CO6761294A2 (es) 2013-09-30
PE20121439A1 (es) 2012-11-06
CL2012000797A1 (es) 2013-08-09
MA33693B1 (fr) 2012-10-01
IL218294A0 (en) 2012-04-30
SG178869A1 (en) 2012-04-27
IN2012DN01913A (enExample) 2015-07-24
US20130011361A1 (en) 2013-01-10
PH12012500648A1 (en) 2012-11-12
AU2010302577A1 (en) 2012-03-15
ECSP12011837A (es) 2012-06-29

Similar Documents

Publication Publication Date Title
BRPI0907826A2 (pt) inibidores heterocíclicos de estearoil-coa desaturase
BR112012007509A2 (pt) derivados pirazóis que modulam estearoil-coa dessaturase
CU23914B1 (es) DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL CoA
MX393345B (es) Composiciones farmaceuticas de moduladores c-met.
SMT201700036B (it) Composti e composizioni come inibitori di protein chinasi
MX337605B (es) Derivados de fumarato de acido graso y sus usos.
ECSP11011340A (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen
GEP201706688B (en) Cdk8/cdk19 selective inhibitors and their use in anti- metastatic and chemopreventative methods for cancer
MX2009003080A (es) Compuestos organicos heterociclicos.
BRPI1014281A2 (pt) azetidinil diamidas como inibidores da monoacilglicerol lipase
MA33976B1 (fr) Spiroindolinone pyrrolidines
PH12014502613A1 (en) Synthesis of heterocyclic compound
MX2009006728A (es) Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd.
GEP20156241B (en) Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
UY34231A (es) Eliminación de inhibidores de la fermentación microbiana de hidrolizados celulósicos u otras composiciones que contienen inhibidores
TN2010000378A1 (en) Heterocyclic inhibitors of stearoyl-coa desaturase
TN2010000598A1 (en) Organic compounds
CU20120052A7 (es) Derivados de pirazol que modulan estearoil-coa-desaturasa
DOP2009000099A (es) Compuestos y composiciones como inhibidores de proteina cinasa
AR078297A1 (es) Composicion de liposoma

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 61/247,634 REIVINDICADA NO PCT/EP2010/064672, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE OS DEPOSITANTES CONSTANTES DA PETICAO DE REQUERIMENTO DO PEDIDO PCT SEREM DISTINTOS DAQUELES QUE DEPOSITARAM A PRIORIDADE REIVINDICADA E NAO APRESENTOU DOCUMENTO COMPROBATORIO DE CESSAO DE TODOS OS INVENTORES DENTRO DO PRAZO DE 60 DIAS A CONTAR DA DATA DA ENTRADA DA FASE NACIONAL, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, ITEM 27 DO ATO NORMATIVO 128/97 E NO ART. 28 DA RESOLUCAO INPI-PR 77/2013.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]